Loomis Sayles & Co. L P Boosts Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Loomis Sayles & Co. L P increased its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 7.2% in the third quarter, according to its most recent filing with the SEC. The fund owned 205,798 shares of the company's stock after acquiring an additional 13,880 shares during the period. Loomis Sayles & Co. L P owned about 0.66% of Medpace worth $68,696,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Independent Advisor Alliance boosted its holdings in shares of Medpace by 16.7% in the third quarter. Independent Advisor Alliance now owns 941 shares of the company's stock valued at $314,000 after purchasing an additional 135 shares during the period. Fisher Asset Management LLC increased its stake in shares of Medpace by 6.9% during the third quarter. Fisher Asset Management LLC now owns 124,399 shares of the company's stock valued at $41,524,000 after buying an additional 8,012 shares during the period. Centaurus Financial Inc. increased its stake in shares of Medpace by 2.0% during the third quarter. Centaurus Financial Inc. now owns 1,513 shares of the company's stock valued at $505,000 after buying an additional 29 shares during the period. Larson Financial Group LLC raised its holdings in shares of Medpace by 2.9% in the third quarter. Larson Financial Group LLC now owns 8,721 shares of the company's stock valued at $2,911,000 after acquiring an additional 244 shares in the last quarter. Finally, Swedbank AB purchased a new stake in Medpace in the third quarter worth about $7,477,000. 77.98% of the stock is currently owned by institutional investors.

Medpace Trading Up 0.0 %

Shares of MEDP stock traded up $0.07 during trading hours on Monday, reaching $337.82. 306,769 shares of the company's stock were exchanged, compared to its average volume of 285,344. Medpace Holdings, Inc. has a 1 year low of $268.80 and a 1 year high of $459.77. The stock has a market cap of $10.50 billion, a PE ratio of 29.96, a PEG ratio of 1.87 and a beta of 1.37. The stock's fifty day moving average price is $340.14 and its two-hundred day moving average price is $373.03.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings data on Monday, October 21st. The company reported $3.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.24. Medpace had a return on equity of 50.87% and a net margin of 17.66%. The firm had revenue of $533.32 million during the quarter, compared to analysts' expectations of $540.99 million. During the same period last year, the business posted $2.22 earnings per share. The company's revenue for the quarter was up 8.3% compared to the same quarter last year. On average, equities analysts expect that Medpace Holdings, Inc. will post 11.93 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on MEDP shares. TD Cowen reduced their price target on shares of Medpace from $413.00 to $372.00 and set a "buy" rating for the company in a report on Wednesday, October 23rd. StockNews.com downgraded shares of Medpace from a "buy" rating to a "hold" rating in a research note on Friday, September 27th. Baird R W downgraded Medpace from a "strong-buy" rating to a "hold" rating in a report on Wednesday, October 23rd. Robert W. Baird boosted their price target on Medpace from $349.00 to $354.00 and gave the stock a "neutral" rating in a research report on Monday. Finally, UBS Group downgraded Medpace from a "buy" rating to a "neutral" rating and dropped their price objective for the company from $420.00 to $350.00 in a research report on Friday, September 27th. Seven analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $380.56.

Medpace Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.